Evidence map›Paper›PMID 19931251›Full record

ArticleExperimental neurology2010

Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice.

Corinne G Jolivalt, Rosemarie Hurford, Corinne A Lee, Wilmar Dumaop, Edward Rockenstein, Eliezer Masliah

Open access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Experimental laboratory models as tools for understanding modifiable dementia risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. A Pathophysiological Intersection of Diabetes and Alzheimer's Disease.International journal of molecular sciences · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Corinne G JolivaltDepartment of Pathology, University of California San Diego, La Jolla, CA 92093-0612, USA. cjolivalt@ucsd.edu
Rosemarie Hurford
Corinne A Lee
Wilmar Dumaop
Edward Rockenstein
Eliezer Masliah
University of California, San Diego · US

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
Tissue Culture CoreP01AG022074 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MASLIAH, ELIEZER · 2003 to 2012
$27.0M
Viral VectorsP01AG010435 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUSZYNSKI, MARK H. · 1991 to 2014
$20.9M
La Jolla Interdisciplinary Neuroscience Center Cores - Vital VP30NS057096 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI LIPTON, STUART A · 2006 to 2010
$12.7M
B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2001 to 2021
$5.2M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
NIA NIH HHS AG022074NIA NIH HHS AG10435NIA NIH HHS AG18440NIA NIH HHS AG5131NIA NIH HHS P01 AG010435NIA NIH HHS P01 AG022074NIA NIH HHS P50 AG005131NIA NIH HHS R01 AG018440NIA NIH HHS R37 AG018440NINDS NIH HHS NS057096NINDS NIH HHS P30 NS057096
6 · The paper itself

Abstract

A number of studies suggest an association between Alzheimer's disease (AD) and diabetes: AD patients show impaired insulin function, whereas cognitive deficits and increased risk of developing AD occur in diabetic patients. The reasons for the increased risk are not known. Recent studies of disturbances in the insulin-signaling pathway have revealed new perspectives on the links between AD and Type 1 diabetes with a particular focus on glycogen synthase-kinase-3 (GSK3). We have therefore characterized a mouse model of combined insulin-deficient diabetes and AD and find that diabetes exaggerated defects in the brain of APP transgenic mice. Mice with combined APP overexpression and diabetes showed a decreased insulin receptor activity and an increased GSK3beta activity. Concomitantly, tau phosphorylation and number of Abeta plaques, the two pathologic hallmarks of AD, were increased in the brain of diabetic-APP transgenic mice. Our results indicate that the pathologic features of AD are exaggerated in the brain of APP transgenic mice that have concurrent insulin-deficient diabetes, and underscore a possible mechanism of brain dysfunction common to AD and diabetes.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsCognitionDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Disease Models, AnimalFemaleGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansInsulysinMaleMaze LearningMiceMice, Inbred C57BLAmyloid beta-Peptidesamyloid beta-protein (1-42)Glycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, mouseInsulysinPeptide FragmentsReceptor, InsulinSynaptophysintau Proteins

Identifiers

PMID19931251
PMCPMC2864332
OpenAlexW1991157941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.